in three specific periods including: within 6 months, in the 1st year, and in the 2nd year post surgery. Importantly, this study accounted for visits that occurred outside a urology clinic as routine PSA tests often occur in a primary care setting.
Design and Data Collection

Study Population and Data Collection
The Washington University Prostate Cancer Prospective Cohort (PCPC) consists of men diagnosed with biopsy confirmed prostate cancer and treated at the Washington University School of Medicine in St. Louis from 2003 to 2010. Sociodemographic information was collected through a mail survey. Recruitment occurred at the time of diagnosis and prior to prostate cancer treatment. Follow-up visit dates, clinical characteristics of disease, and treatment type were determined by medical records abstraction. There was a biannual review of medical charts. Men that received follow-up care outside the Washington University School of Medicine system were contacted by phone and mail, and medical records were obtained from the current provider. Follow-up of medical records was 98% complete. Participant consent was obtained at time of enrollment, and the study was approved by the Institutional Review Board at the Washington University in St. Louis School of Medicine.
One thousand two hundred and seventeen men with prostate cancer enrolled in the Washington University PCPC and fully completed the survey. Men who identified as Black or White and were treated with radical prostatectomy were eligible for the current study. Men with an unknown surgery date or missing any covariate information were excluded. The final analytic sample consisted of 1,158 men.
Predictors, Outcome, and Statistical Analysis
The primary outcomes of interest were follow-up urology visits within 6 months, in the 1st year, and in the 2nd year post radical prostatectomy, based on ACS and NCCN recommended guidelines. To further capture all post-surgery follow-up visits that may have occurred at a primary clinic, in a secondary analysis all visits with a PSA test regardless of provider type were examined. Visits that occurred in the first 6 weeks after surgery were excluded to ensure that visits for routine postoperative care were not captured.
Key predictors of follow-up that were evaluated included age at surgery, race, residence, education, marital status, and disease aggressiveness. Age at surgery and disease aggressiveness were determined using medical records. Age at surgery was defined as age at time of radical prostatectomy. Disease aggressiveness was determined using pathological Gleason sum and stage at time of radical prostatectomy. High-risk prostate cancer was defined as a pathological Gleason sum of 4+3, Gleason sum ≥8, or pathological stage ≥T3. All other men were included in the low-risk group. Race (Black or White), education (less than college vs. some college or more), and marital status (married vs. not married) were all based on self-report. Residence at surgery (urban vs. rural) was determined using census-tract Rural-Urban Commuting Area Codes (Unites States Department of Agriculture, 2017).
Logistic regression was used to assess the association between each of the predictors and having a follow-up urology visit at three time periods post radical prostatectomy: in 6 months, in the 1st year, and in the 2nd year. Each predictor was evaluated independently (unadjusted model) and in a multivariable model that included all predictors (age at surgery, race, residence, education, marital status, and disease aggressiveness). In a secondary analysis, all follow-up visits with a PSA test, regardless of provider type, were examined using the approach described previously.
All analyses were conducted using SAS 9.4 (Cary, NC).
Findings
Characteristics of the study cohort are presented in Table  1 . The mean age at time of radical prostatectomy was 61 years. The majority of research participants were White (93.9%, n = 1,087). Most men resided in an urban residence (65.8%, n = 762), had some college education or above (72.5%, n = 840), and were married (86.1%, n = 997) at time of prostate cancer diagnosis. Approximately a third of the patient sample (n = 382) has high-risk prostate cancer based on a combined measure of Gleason sum and stage. Sixty-eight percent (n = 787) of men had a follow-up visit within 6 months of surgery and 82.8% (n = 959) had a follow-up visit within 1 year of surgery. During the 2nd year post surgery, 64.4% (n = 746) patients had a urology visit. The proportion of patients with follow-up visits increased when non-urology visits with a PSA test were included.
See Table 2 for predictors of follow-up visits with a urologist. Black race was associated with a reduced odds of urology follow-up visits within 6 months (OR: 0. No association was observed between age at surgery, education, and disease aggressiveness at any time period.
In a secondary analysis of all visits with a PSA test regardless of provider type ( 
Recommendations and Limitations
In this longitudinal study, men who were Black, lived in a rural residence, or were unmarried were less likely to have follow-up visits with a urologist at ACS and NCCN recommended time points. Black men were significantly less likely to receive follow-up care even when for follow-up visits that did not occur with a urologist were accounted for. This study is among the first studies to examine predictors of follow-up among prostate cancer patients more than a year after diagnosis, a clinically important period where patients remain at risk for biochemical recurrence (Kolodziej, 2014; Paller & Antonarakis, 2013) .
Consistent with this study, in a SEER-Medicare cohort, Onukwugha et al. reported that Black men with prostate cancer were less likely to see a urologist while married men or those residing in an urban residence were more likely to see a urologist within 1 year of diagnosis (Onukwugha et al., 2014) . The results of this study build on Onukwugha et al. by examining follow-up visits within 6 months and during the 2nd year in addition to 1st year. Moreover, Onukwugha et al. was limited to elderly men on Medicare (≥ 65 years), with a mean age of prostate cancer diagnosis of 74 years (Onukwugha et al., 2014) . By contrast, the mean age at prostate cancer diagnosis in this study was 61, increasing the generalizability of the results to younger men with prostate cancer. A strength of this study is that it captured visits that occurred outside urology. This is necessary as routine PSA tests often occur in the primary care setting.
Despite guidelines suggesting follow-up PSA screenings every 6-12 months following prostate cancer treatment, the study results suggest that a quarter of prostate cancer patients don't receive follow-up care just 6 months after surgery even when visits that occur outside a urology clinic are accounted for (Skolarus et al., 2014) . The results suggest that the receipt of timely and guidelineconcordant care can be challenging for prostate cancer survivors.
Cancer patients often receive limited posttreatment guidance. A survey of oncologists reported that only 64% always or almost always discuss survivorship care with patients (Blanch-Hartigan et al., 2014) . Moreover, only 32% of oncologists discussed who would provide follow-up care and less than 5% provided a written survivorship care plan (Blanch-Hartigan et al., 2014) . Beyond limited patient guidance, there is a lack of clarity on who should be responsible for follow-up care. Fifty-one percent of primary care providers (PCPs) support a shared care model between PCPs and specialty providers, while 59% of specialists strongly support oncology-based survivorship care, according to a randomly distributed national survey of physicians (Cheung et al., 2013) . There is some evidence that cancer survivors may be reluctant to get cancer-related follow-up care from PCPs (Hudson et al., 2012) . In fact, cancer survivors may be less likely to receive adequate follow-up care even for noncancer-related health issues (Earle & Neville, 2004) .
The dearth of patient guidance and care coordination is compounded by other factors that can impede adequate follow-up care (Jacobs & Shulman, 2017) . Lack of social support and psychosocial stress can also be a contributing factor. This study reported that unmarried men were less likely to have follow-up visits with a urologist after 2 years. This is consistent with other studies that have reported that unmarried men with prostate cancer are at greater risk of death than married men with prostate cancer (Abdollah et al., 2011; Tyson et al., 2013) . Other challenges faced by prostate cancer survivors include limited access to care, cost, fear of recurrence, and long-term treatment effects (Davis et al., 2014; Jacobs & Shulman, 2017) .
The multitude of challenges faced by cancer survivors clearly suggests the need for increased guidance post treatment. A survey of breast and prostate cancer survivors reported that about 50% of patients would like to receive more information on survivorship care (O'Malley et al., 2016) . In particular, patients with comorbidities and Black patients are most likely to want additional information regarding follow-up care (O'Malley et al., 2016) . This is consistent with the findings of this study, where Black men were more likely to receive inadequate follow-up care at all three time periods, both at a urologist or other provider that provided a PSA test. d Models included age at surgery, race, residence, education, marital status, and disease aggressiveness. *Statistically significant at α = .05.
Increased care coordination between patients, providers, and communities is needed to help ensure that prostate care patients receive adequate follow-up care. Although the primary urologist is responsible for followup care until there is an explicit transfer of responsibility to a primary care physician, such clinical coordination is not routine (Jacobs & Shulman, 2017; Skolarus et al., 2014) . The American Society of Clinical Oncology recommends strategies to be in place that "ensure that every survivor receives a written coordinated treatment summary and follow-up plan" (Jacobs & Shulman, 2017) . However, such plans are not often effectively implemented due to lack of reimbursement, uncertainty over who is responsible for implementation, lack of care coordination, and limited evidence on effectiveness (Jacobs & Shulman, 2017) . Nonetheless, improved care coordination and survivorship care plans have the potential to improve follow-up. Other potential strategies include academic-public partnerships that work together to broadly disseminate information regarding survivorship (Skolarus et al., 2017) .
In this study, several groups that may benefit from increased guidance and support regarding follow-up care were identified, including Black men, men that are unmarried, or men that live in a rural residence. Although this study is limited to a single institution, key strengths of this study include examining follow-up care at three distinct time periods and identification of patient characteristics that are associated with a decreased likelihood of followup visits. Long-term survivorship care plans and clear clinical pathways, particularly for patients that are at increased risk for not receiving follow-up visits, could improve survivorship care for prostate cancer patients (Jacobs & Shulman, 2017) .
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